Squarepoint
LRMR icon

Squarepoint’s Larimar Therapeutics LRMR Stock Holding History

Squarepoint’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-30,416
Closed -$116K – 4669
2025
Q4 		$116K Buy
+30,416
New +$118K ﹤0.01% 4013
2025
Q1 		– Sell
-28,071
Closed -$109K – 5072
2024
Q4 		$109K Sell
28,071
-14,724
-34% -$97.2K ﹤0.01% 4680
2024
Q3 		$280K Buy
42,795
+12,937
+43% +$104K ﹤0.01% 3497
2024
Q2 		$216K Buy
+29,858
New +$229K ﹤0.01% 3619
2023
Q2 		– Sell
-30,655
Closed -$139K – 3819
2023
Q1 		$139K Buy
+30,655
New +$160K ﹤0.01% 2904
2020
Q2 		– Sell
-865
Closed -$8K – 2392
2020
Q1 		$8K Sell
865
-2,137
-71% -$28.1K ﹤0.01% 1784
2019
Q4 		$40K Buy
+3,002
New +$28.7K ﹤0.01% 2406
2019
Q2 		– Sell
-1,542
Closed -$51K – 2548
2019
Q1 		$51K Sell
1,542
-5,321
-78% -$273K ﹤0.01% 2080
2018
Q4 		$408K Buy
6,863
+2,938
+75% +$290K ﹤0.01% 1360
2018
Q3 		$551K Buy
3,925
+2,867
+271% +$348K 0.01% 1255
2018
Q2 		$130K Buy
+1,058
New +$89.9K ﹤0.01% 1617
2018
Q1 		– Sell
-1,575
Closed -$87K – 1941
2017
Q4 		$87K Sell
1,575
-2,292
-59% -$103K ﹤0.01% 1974
2017
Q3 		$163K Buy
3,867
+2,870
+288% +$119K ﹤0.01% 1439
2017
Q2 		$42K Buy
+997
New +$51K ﹤0.01% 1466
2017
Q1 		– Sell
-904
Closed -$35K – 1739
2016
Q4 		$35K Buy
+904
New +$36.7K ﹤0.01% 1711
2016
Q2 		– Sell
-5,708
Closed -$458K – 1244
2016
Q1 		$458K Buy
5,708
+4,241
+289% +$335K 0.04% 659
2015
Q4 		$111K Buy
+1,467
New +$236K 0.01% 1122

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Squarepoint's LRMR Position: Q1 2026 in Review

Squarepoint sold out of Larimar Therapeutics (LRMR) in Q1 2026, closing a stake of 30,416 shares — an estimated $116K sold.

Squarepoint first reported a position in LRMR in Q4 2015 and held it in 17 quarters. The position peaked at $551K in Q3 2018. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

  • Squarepoint reported no remaining Larimar Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Squarepoint sold 30,416 Larimar Therapeutics shares in Q1 2026, an estimated $116K.
  • Squarepoint first reported a position in Larimar Therapeutics in Q4 2015 and held it in 17 quarters.
  • Squarepoint's Larimar Therapeutics position peaked at $551K in Q3 2018.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.